Introduction
============

The application of permanent magnets for treating specific medical problems such as arthritis, chronic pain syndromes, wound healing, insomnia, headache and others has steadily increased during the last decade. Data Research-2000 reported \$350 million in sales of therapeutic magnets in the USA and \$4 billion worldwide in 1999. Magnets marketed directly to consumers are considered safe by the National Center of Complementary and Alternative Medicine (NCCAM) <http://nccam.nih.gov/health/magnet/magnet.htm>.

Results from basic science research demonstrating certain biological effects of static magnetic field (SMF) therapy provide a rationale for investigating potential clinical benefits of SMFs ([@B1; @B2; @B3; @B4; @B5]). In addition, NCCAM has funded human studies to evaluate the effectiveness of SMFs for patients with fibromyalgia ([@B6]) and carpal tunnel syndrome ([@B7]). Despite the lack of scientific recommendations for SMF dosage and treatment regimens, multiple clinical trials have been conducted to evaluate SMF efficacy. Dosing parameters such as the optimal SMF strength, frequency and duration of magnet application and at what time point during the course of an illness or injury the SMF should be applied, are not established for any specific clinical indication.

As we begin to evaluate whether SMF therapy is efficacious in humans, a critical need exists for understanding and precisely defining SMF dosages and treatment regimens. Our objectives for this critical review are to: (i) summarize SMF studies involving the application of permanent magnets in humans; (ii) critically evaluate the reporting quality of 10 essential SMF dosing and treatment parameters and (iii) propose a set of criteria for reporting SMF treatment parameters in future clinical trials.

This review does not report clinical outcomes because, during a preliminary evaluation of the identified studies, it was apparent that many lacked a sufficiently detailed description of SMF dosage and treatment parameters to characterize the SMF dose delivered to the target tissue. We reasoned that if the SMF dose were inadequate or inappropriate for the clinical indication, inferences drawn from the reported results might be misleading.

Methods
=======

Data Sources and Search Strategy
--------------------------------

A professional librarian (NH) searched 27 electronic databases from the time each database was developed through September 30, 2006, to identify clinical studies involving the use of SMF in humans ([Table 1](#T1){ref-type="table"}). Various search strategies were employed depending on the size and scope of the database. In some cases, a simple keyword search using the term 'magnet' was sufficient to retrieve relevant articles with reasonable precision and recall. In other cases, a more sophisticated strategy involving multiple synonyms for SMF therapy, subject headings, truncation and excluded terms was required. The primary author examined the results of the searches to identify articles for analysis, screening by title, abstract when it was available and full text where necessary. The bibliographies from relevant original research, reviews ([@B8; @B9; @B10]), and a key textbook in the SMF field ([@B11]) were searched to identify additional references. Table 1.Databases searchedDatabaseCoverage datesAcubriefs.com1999 till presentAgency for Healthcare Research and Quality (AHRQ) websiteWebsite: no coverage dates givenAlt HealthWatch1984 to September 2006AMEDca. 1980 till presentAnnual Reviews Online1932--1999Applied Science and Technology Index1983 till presentArticleFirst1990 till presentBIOSIS Previews1990 till presentChina Academic Journals (CAJ)1994 till presentCINALH1982 till presentDatadiwanUnable to determine; no response from database producerDIMDI (German Institute of Medical Documentation and Information)Federated search of multiple databases -- various coverage datesDissertation Abstracts International1861 till presentEMBASE.com1974 till present + MEDLINEExtraMED1992--2000Global Health1973 till presentHOM-INFORM (British Homeopathic Library)Unable to determine; no response from database producerIndex to Chiropractic Literature1985 till presentJICST--Eplus---Japanese Science & Technology1985 till presentMANTIS1900 till presentMedicLatina1998 till presentNatural StandardN/A (Periodically updated-monograph)NHS Centre for Reviews and Dissemination1994 till presentPASCAL1973 till presentPubMed1950 till presentScienceDirect Health & Life Sciences1996 till presentSPORTDiscus1830 till present

Inclusion and Exclusion Criteria
--------------------------------

Studies were selected for inclusion using the following criteria.

### Publication type

Only English language articles were identified due to limited funding for accurate translation. Abstracts, posters and editorials were excluded because they were unlikely to provide sufficient information with which to evaluate the SMF treatment parameters.

### Study design

Clinical trials, case series, case reports and observational studies were included because our goal was to summarize and evaluate all SMF treatment parameters that have been described.

### Clinical indication

We included studies involving any clinical diagnosis or medical condition in humans. Studies evaluating physiological change as a result of magnet application in healthy volunteers were also included.

### Type of magnetic field therapy

Only studies involving the application of SMFs via a permanent magnet were included. Excluded were studies reporting on electromagnetic field therapy, magnetic fields generated by applying DC to a coil, transcranial magnetic stimulation. Also excluded were studies reporting on the use of magnets on acupuncture points. We believe the stimulation of acupuncture points by means of a magnetic field may work via a systemic mechanism ([@B12]) different from that occurring as a result of a magnetic field applied directly to an anatomical/pathological target tissue.

Data Extraction
---------------

Data were extracted from each article on clinical indication, study design and 10 essential SMF treatment parameters. An 'essential treatment parameter' was defined as a key component of the SMF dosage or treatment regimen that needed to be clearly described to characterize the magnetic field dose that was delivered to the target tissue. The 56 articles ([@B6], [@B13; @B14; @B15; @B16; @B17; @B18; @B19; @B20; @B21; @B22; @B23; @B24; @B25; @B26; @B27; @B28; @B29; @B30; @B31; @B32; @B33; @B34; @B35; @B36; @B37; @B38; @B39; @B40; @B41; @B42; @B43; @B44; @B45; @B46; @B47; @B48; @B49; @B50; @B51; @B52; @B53; @B54; @B55; @B56; @B57; @B58; @B59; @B60; @B61; @B62; @B63; @B64; @B65; @B66; @B67]) that met our inclusion/exclusion criteria were randomly distributed to five data extractors.

Quality Assessment (QA) for Reporting SMF Treatment Parameters
--------------------------------------------------------------

A QA score was developed to quantify how completely each of 10 dosing parameters: SMF characteristics (magnet materials, dimensions, pole configuration, field strength); SMF application (frequency, duration, site of application and support device) and target (target tissue and distance of magnet from target tissue) was described. Two points were given if a parameter was described in enough detail to allow replication of the study protocol by other investigators. One point was given if the parameter was only partially described but enough detail was given to make reasonable inferences about that parameter. For example, if the magnet material was not described but the manufacturer\'s name (e.g. Bioflex) was provided, and one of the evaluators was familiar enough with that company\'s products to know that the product was most likely a flexible-type magnet, one point was given. One point was also given if the target tissue was not specifically named, but implied. For example, when dysmenorrhea was treated by placing a magnet over the lower abdomen, the evaluators assumed the target was the uterus. The evaluators might also have inferred that the target was a trigger point on the abdominal wall. Zero points were assigned if the essential parameter was not described at all. A perfect QA score is 20.

Three evaluators (APC, a clinician researcher with 14 years clinical experience in the therapeutic use of SMFs; MM, a biophysicist with 32 years research experience in SMFs and JS, a magnetic product developer with 15 years experience in magnet design and manufacturing) met to discuss the extracted data and assign a consensus QA score for reporting each of the 10 essential SMF treatment parameters in the 56 studies.

Results
=======

The complete set of extracted data on 10 essential SMF treatment parameters and the QA scores for the 56 studies are summarized in [supplementary Tables 1 and 2](http://ecam.oxfordjournals.org/cgi/content/full/nem131/DC1).

Description of Studies
----------------------

Forty-two studies were conducted in patient populations ([supplementary Table 1](http://ecam.oxfordjournals.org/cgi/content/full/nem131/DC1)) and 14 in healthy volunteers ([supplementary Table 2](http://ecam.oxfordjournals.org/cgi/content/full/nem131/DC1)). The varied clinical conditions and physiological responses that were evaluated are listed in [Table 2](#T2){ref-type="table"}. In the 56 studies, 39 different physiological or pathological conditions are represented. The most common clinical diagnosis was osteoarthritis of the knee. Other conditions were as diverse as peripheral neuropathy, peripheral vascular disease, wound and ulcer healing, obstructive sleep apnea, tinnitus and a variety of chronic pain syndromes. The physiological outcomes measured were also disparate including: improvement in muscle strength, muscle soreness post exercise, postural sway, fine touch, blood flow and heart rate and blood pressure. The majority of studies were randomized controlled trials (RCTs) (*n* = 41) that included both crossover designs and within-subject comparisons. We identified only two Phase I/II studies that assessed dose ranging or an evaluation of dosing regimens ([@B16; @B17; @B18; @B19; @B20; @B21; @B22; @B23; @B24; @B25; @B26; @B27; @B28; @B29; @B30; @B31; @B32; @B33; @B34; @B35; @B36; @B37; @B38; @B39; @B40; @B41; @B42; @B43; @B44; @B45; @B46; @B47; @B48; @B49; @B50]). Table 2.Conditions treated with static magnetic field therapyPhysiological Conditions[^a^](#TF1){ref-type="table-fn"}Clinical Conditions[^b^](#TF1){ref-type="table-fn"}Muscle strength/physical function ([@B21], [@B51], [@B55], [@B58], [@B31])***Chronic pain*** -- headache ([@B40]), neck ([@B37]), shoulder ([@B38], [@B39], [@B47]), low back ([@B25], [@B35], [@B41], [@B63]), abdominal/genital ([@B36]), pelvic ([@B18], [@B29]), foot ([@B20], [@B60], [@B61], [@B64; @B65; @B66]), fibromyalgia ([@B6], [@B23]), myofascial pain ([@B48], [@B59]), carpal tunnel syndrome ([@B19], [@B62])Induced muscle soreness ([@B17], [@B46], [@B49])***Arthritides*** -- knee ([@B34], [@B35], [@B52], [@B53], [@B67]), hip ([@B32])HR and BP ([@B33])***Post surgical*** -- suction lipectomy ([@B42]), hallux valgus ([@B54])Blood flow/temperature ([@B14], [@B43; @B44; @B45], [@B56])***Peripheral vascular disease/leg or foot ulcerations*** -- ([@B13], [@B28], [@B30], [@B57])***Miscellaneous*** -- bronchopulmonary dysplasia ([@B22]), sleep apnea ([@B26], [@B27]), urinary incontinence ([@B15]), tinnitus ([@B24]), orthodontic safety ([@B16]), malignancy ([@B50])[^1]

Since there were two distinct categories of studies (healthy volunteers and patient populations), a multivariate analysis (MANOVA) was used to compare them on the 10 treatment parameters evaluated by QA score. The MANOVA was not significant, *P* \> 0.20. Thus, there was no need to consider reporting quantitative or qualitative results for the two groups separately.

QA Scores
---------

Percentage of the 56 studies that scored either 2 (fully described), 1 (partially described) or 0 (not described) on each essential treatment is delineated in [Fig. 1](#F1){ref-type="fig"}. Two studies ([@B45; @B46; @B47; @B48; @B49; @B50; @B51; @B52; @B53; @B54; @B55; @B56; @B57; @B58; @B59; @B60; @B61; @B62; @B63; @B64; @B65; @B66; @B67]) out of 56 received a perfect QA score of 20 for detailed reporting of SMF dosing parameters. Twenty-four studies (43%) scored 15--19 for adequacy of reporting SMF treatment parameters; 20 studies (36%) scored 10--14: 9 studies (16%) scored 5--9 and one scored less than 5. The dosing parameters most consistently well reported were site, frequency and duration of magnet application. The parameters most often poorly reported were characteristics of the magnet (magnet dimensions, field strength measured at the magnet surface) and estimated distance of the magnet from the target tissue. Only 22 (39%) of 56 articles ([@B6], [@B14], [@B16], [@B18], [@B23], [@B29], [@B31; @B32; @B33; @B34; @B35], [@B40; @B41; @B42], [@B44], [@B45], [@B52], [@B53], [@B56], [@B59], [@B64], [@B67]) provided sufficiently detailed information on SMF treatment parameters to permit other investigators to attempt study replication. Figure 1.Quality of reporting 10 static magnetic field (SMF) dosage and treatment parameters was assessed in 56 human studies. Quality Assessment (QA) score 2 = parameter is reported with enough detail for study replication; 1 = parameter is reported with insufficient detail to allow study replication or accurate comparison of results with other studies; 0 = parameter is not reported.

Discussion
==========

This critical review was undertaken to summarize SMF research involving the application of magnets in humans; to critically evaluate quality of reporting10 essential SMF dosage and treatment parameters and to propose a set of criteria for reporting SMF treatment parameters in future clinical trials.

Since research on SMF therapy in humans is in an emerging state, it is vital that we lay the groundwork for the rigorous conduct of future clinical trials. A fundamental component of trial methodology is the assurance that optimal SMF dosage and treatment parameters are established for each clinical condition under study. If the applied SMF is of insufficient strength to reach its target or if the frequency or duration of application is inadequate for the medical condition, trial results might be invalid or misleading. Such a situation could be likened to conducting a trial to evaluate the effectiveness of the antibiotic doxycycline for treating Mycoplasma pneumonia. If patients in the study are given a single 100 mg dose of the antibiotic, the results might show no significant improvement. It would, however, be erroneous to infer from these results that doxycycline is ineffective for treating Mycoplasma pneumonia.

In order to judge the adequacy of SMF exposure for a particular clinical indication, the magnetic dosage and treatment regimens need to be reported explicitly. Clear reporting also allows for accurate replication of study protocols and comparison of results between studies. This critical review revealed that the majority of published studies (61%) failed to report enough detail about 10 essential SMF dosage and/or treatment parameters to characterize the SMF that actually reached the intended target tissue. Of the 10 essential SMF treatment parameters reported, only site, frequency and duration of magnet application and magnetic support device were adequately described. Descriptions of three other essential treatment parameters specific to SMF dosing, i.e. identification of the target tissue, measurement of the SMF at the magnet\'s surface and estimation of distance of target tissue from the magnet, were either not described or only partially described in a preponderance of studies ([Fig. 1](#F1){ref-type="fig"}).

In addition, the SMF dosage reported in many of the studies revealed a limited understanding, on the part of the investigators, of the physical and biophysical characteristics of magnets that determine the SMF dose ultimately delivered to the target tissue. Four studies provided contradictory information about the material composition of the magnetic devices applied ([@B31], [@B44], [@B55], [@B61]). Other studies provided ambiguous descriptions of the magnetic strength, by not defining whether they were reporting the manufacturer\'s Gauss rating or the surface field strength. Approximately one-half of the investigators ([@B13], [@B15], [@B17], [@B21], [@B22], [@B24], [@B26; @B27; @B28; @B29; @B30; @B31], [@B36], [@B40], [@B43], [@B46; @B47; @B48; @B49], [@B51], [@B54], [@B55], [@B58; @B59; @B60; @B61; @B62], [@B68]) failed to record measurements of the field strength at the surface of their magnets. In 16 studies ([@B15; @B16; @B17], [@B19], [@B21], [@B26], [@B27], [@B39], [@B46], [@B48], [@B49], [@B51], [@B54], [@B56], [@B58], [@B63]) there is no mention of which pole configuration was applied or if the side of the magnet facing the skin was north, south or alternating polarity.

Despite a lack of established recommendations or guidelines for SMF dosing regimens, 41 RCTs, were conducted without prior benefit of Phase I or II trials to optimize SMF dosage and treatment regimens for the condition being treated. In fact, this review identified only two early phase studies that addressed toxicity and/or dose ranging of SMFs ([@B16], [@B50]).

### Limitations to this review

There are a number of limitations in our study. First, we reviewed only the English language literature. Use of therapeutic magnets has a long history in China, Japan and the former Eastern European Bloc countries. Also, several Asian manufacturers that produce magnetic bracelets and necklaces have an extensive literature on clinical usage. Second, although we found a large body of literature reporting the use of magnets on acupuncture points, these studies were excluded because we believe that the practice of acupuncture (a systemic approach) entails a different therapeutic paradigm than direct application of the magnet to a localized anatomical site. Third, evaluators were not blinded to the studies they scored. Since the available clinical SMF research at this time is so small, the three evaluators were already familiar with many of the studies, making it impossible to blind them as to authorship. Fourth, our search ended on September 30, 2006, and does not include any publications after that date.

Conclusion and Directions for Future Research
=============================================

Complete descriptions of the SMF dose that was applied to human participants are notably lacking in the majority of SMF therapy studies published to date. Without knowing the SMF dose that was delivered to the target tissue, we cannot draw meaningful inferences from clinical trial results. As research on SMF therapy progresses, engineers, physicists and clinicians need to continue to work together to optimize SMF dosage and treatment parameters for each clinical condition. Future publication of SMF studies should include an explicit assessment of the SMF dosage and treatment parameters outlined in this review, so as to be able to replicate previous studies, validly assess outcomes and make objective, scientific comparisons between studies.

Supplementary Data
==================

[Supplementary data](http://ecam.oxfordjournals.org/cgi/content/full/nem131/DC1) are available at eCAM Online.

[^1]: ^a^Physiological outcomes evaluated in healthy volunteers; ^b^Clinical indications in various patient populations.
